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Abstract: The proinsulin connecting peptide, C-peptide, is a cleavage product of insulin 
synthesis that is co-secreted with insulin by pancreatic β-cells following glucose stimulation. 
Recombinant insulin, used in the treatment of diabetes, lacks C-peptide and preclinical and 
clinical studies suggest that lack of C-peptide may exacerbate diabetes-associated complications. 
In accordance with this, several studies suggest that C-peptide has beneﬁ  cial effects in a number 
of diabetes-associated complications. C-peptide has been shown to prevent diabetic neuropathy 
by improving endoneural blood ﬂ  ow, preventing neuronal apoptosis and by preventing axonal 
swelling. In the vascular system, C-peptide has been shown to prevent vascular dysfunction in 
diabetic rats, and to possess anti-proliferative effects on vascular smooth muscle cells, which 
may prevent atherosclerosis. However, C-peptide depositions have been found in arteriosclerotic 
lesions of patients with hyperinsulinemic diabetes and C-peptide has been shown to induce 
pro-inﬂ  ammatory mediators, such as nuclear factor kappa B, inducible nitric oxide synthase, and 
cyclooxygenase-2, indicating that C-peptide treatment could be associated with side-effects that 
may accelerate the development of diabetes-associated complications. This review provides a 
brief summary of recent research in the ﬁ  eld and discusses potential beneﬁ  cial and detrimental 
effects of C-peptide supplementation.
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Introduction
The vascular endothelium is pivotal in all aspects of cardiovascular physiology and 
pathology. It is well known that patients with diabetes mellitus are subject to an 
increased risk of developing atherosclerosis, which is the principal cause of heart 
attack, stroke, and gangrene of the extremities. Diabetes accelerates atherosclerosis 
(Brownlee 2001), microangiopathy and abnormalities in small vessel function, 
complications that signiﬁ  cantly contribute to diabetes-induced morbidity (Jensen et al 
1989). Aggressive treatment of hyperglycemia has been shown to be associated with a 
decrease in diabetes-associated complications, but is not sufﬁ  cient to fully normalize 
the incidence of cardiovascular disease in patients with diabetes (DCCT 1993). This 
clinical observation suggests that there may be other factors that causally contribute 
to the development of diabetes complications.
During insulin biosynthesis, the hormone is synthesized as a single polypeptide, 
proinsulin, which is subsequently proteolytically processed into insulin inside insulin 
granules. The mature hormone consists of two polypeptides, the so called A- and 
B-chain, while the connecting peptide is detached and released into the circulation. 
This proinsulin-connecting peptide, ie, C-peptide, is thus a product of insulin synthesis, 
and is released together with the mature hormone during hyperglycemia. Thus, 
when insulin synthesis is impaired, patients will also become C-peptide-deﬁ  cient. Vascular Health and Risk Management 2008:4(6) 1284
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However, recombinant insulin does not contain the C-peptide 
and recent research indicates that this peptide may play 
an important physiological role. The current knowledge 
regarding the effects of C-peptide on proliferation, immune 
response, and cell growth will be reviewed brieﬂ  y.
Beneﬁ  cial effects of C-peptide
Exogenous C-peptide administration has beneﬁ  cial effects in 
many tissues commonly affected by diabetic complications, 
a ﬁ  nding supported by the fact that pancreas transplantation 
reduces diabetic lesions after ten years of normoglycemia, 
when compared to treatment with recombinant insulin 
(Fioretto et al 1998; Fiorina et al 2003). Diabetes-induced 
cardiovascular complications, such as decreased blood 
ﬂ  ow in the extremities, have been shown to be prevented 
by C-peptide (Johansson et al 1992, 2003; Forst et al 
1998b; Hansen et al 2002). In addition, C-peptide improves 
diabetes-induced erythrocyte deformability, which in turn 
likely improves oxygen availability and uptake in affected 
tissues (Johansson et al 1992; De la Tour et al 1998; Kunt 
et al 2000). Furthermore, C-peptide prevents diabetic 
neuropathy via improvements of endoneural blood ﬂ  ow and 
by preventing axonal swelling (Johansson et al 2000; Sima 
et al 2004). In the kidneys, C-peptide prevents renal damage 
by reducing glomerular hyperﬁ  ltration, hypertrophy, and 
proteinuria (Forst et al 1998a; Sjoquist et al 1998; Johansson 
et al 2000; Samnegard et al 2001, 2004; Huang et al 2002; 
Nordquist et al 2007; Stridh et al 2008). Several studies report 
a reduction of microvascular complications in patients with 
type 1, as well as type 2, diabetes with circulating concen-
trations of C-peptide close to physiological levels (Fiorina 
et al 2003; Manzella et al 2003; Steffes et al 2003; Sari and 
Balci 2005; Shapiro et al 2006). Pancreatic transplantation, 
which restores not only insulin secretion, but also that of 
C-peptide, is associated with prevention and even reversal of 
diabetic complications (Lee et al 2006). Despite this, recent 
research indicates that C-peptide may not be beneﬁ  cial under 
all circumstances.
Type 2 diabetes is a disease associated with endothelial 
dysfunction and the development of insulin resistance. 
Type 2 diabetes progresses through two stages. In the ﬁ  rst 
stage, tissue insulin action decreases, resulting in increased 
insulin and C-peptide production. The second stage is reached 
when “pancreatic exhaustion” causes insulin and C-peptide 
production to cease. Thus, during disease progression, 
patients exhibit high circulating concentrations of C-peptide. 
Atherosclerosis is an inﬂ  ammatory process, and in addition to 
hemodynamic and metabolic factors, inﬂ  ammation appears 
to be a potential pathogenic mechanism in the development 
of the disease (Navarro et al 2003). Although it has not been 
elucidated whether type 2 diabetics suffer from inﬂ  ammation 
to a greater extent than type 1 diabetic patients, plasma levels 
of interleukin-6 (IL-6) appear to be associated with C-peptide 
concentrations in type 2 diabetic patients (Heliövaara et al 
2005). Interestingly, C-peptide depositions have been found 
in arteriosclerotic lesions of patients with diabetes (Marx 
et al 2004).
Effects of C-peptide on cell 
proliferation and apoptosis
Atherosclerosis is characterized by features of chronic 
inﬂ  ammation and proliferative processes. In the development 
of atherosclerosis, pathological proliferation and migration 
of vascular smooth muscle cells are critically involved in 
the formation of atherosclerotic plaques. C-peptide has 
been shown to prevent vascular dysfunction in diabetic 
rats (Ido et al 1997), and to possess antiproliferative effects 
on vascular smooth muscle cells (Kobayashi et al 2005), 
which indicates that treatment with C-peptide may delay 
disease progression in atherosclerosis. The administration of 
C-peptide (1 to 100 nM) appears to suppress hyperglycemia-
induced hyperproliferation of aortic smooth muscle cells 
(Kobayashi et al 2005). The antiproliferative effects of 
C-peptide on vascular smooth muscle cells are mediated 
through the inhibited expression of the platelet-derived 
growth factor-β (PDGF-β) receptor and increased phos-
phorylation of mitogen-activated protein kinase (MAPK) 
(Kobayashi et al 2005). This stimulating effect on MAPK 
has been described also for other cell types and experimental 
settings (Kitamura et al 2001; Zhong et al 2004, 2005). Para-
doxically, in other studies, C-peptide has been reported to 
act as a mitogen by the induction of vascular smooth muscle 
cell proliferation (Walcher et al 2006), a ﬁ  nding suggesting 
proatherogenic activities of the peptide. Whether these effects 
occur in vivo remains to be determined.
Atherosclerotic lesions originate from inﬂ  ammatory and 
proliferative responses elicited by injuries to the endothelium 
and smooth muscle of arterial walls. A large number of 
growth factors, as well as cytokines, chemokines, and 
vasoregulators, interact to initiate and propagate the disease. 
The transcription factor nuclear factor kappa B (NF-κB) is 
of particular interest and plays a pivotal role in the early 
stages of disease progression. NF-κB orchestrates transcrip-
tion of genes encoding various cell-adhesion molecules, 
as well as inducible nitric oxide synthase (iNOS). NF-κB 
can be activated by inﬂ  ammatory and proliferative stimuli Vascular Health and Risk Management 2008:4(6) 1285
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(Witztum and Steinberg 1991), and activated NF-κB is 
found in vascular smooth muscle cells, endothelial cells, and 
macrophages in atherosclerotic lesions of human patients 
(Brand et al 1996). It has been postulated that NF-κB 
promotes chronic inﬂ  ammation and may accelerate diabetic 
vascular disease. In this context, it is of importance that 
NF-κB activity is increased during hyperglycemia (Pieper 
and Riaz-ul-Haq 1997; Yerneni et al 1999). The inhibition 
of protein kinase C (PKC), an upstream regulator of NF-κB 
activity, has been shown to inhibit hyperglycemia-induced 
NF-κB activation in vascular smooth muscle cells and aortic 
endothelial cells (Pieper and Riaz-ul-Haq 1997; Yerneni 
et al 1999). In Swiss 3T3 ﬁ  broblasts, C-peptide (1 nM) has 
been shown to stimulate the PKC/NF-κB signaling pathway 
(Kitazawa et al 2006).
During disease progression in type II diabetes there 
is typically an increase in circulating concentrations of 
C-peptide. This correlation may indicate that C-peptide 
has negative effects on diabetes-associated complications. 
Alternatively, it is possible to argue that C-peptide is indeed 
renoprotective, and that disease progression would be further 
accelerated in the absence of the peptide. Notably, diabetes-
associated complications normally develop slower in patients 
with type I diabetes, where patients have a relative lack of 
C-peptide, as compared to patients with type II diabetes, 
where patients typically have increased circulating C-peptide. 
However, potential mechanisms for this discrepancy have not 
been thoroughly investigated. In this context, it is intriguing 
that serum concentrations of the cytokine tumor necrosis 
factor-alpha (TNF-α) correlates with plasma C-peptide 
concentrations (Hotamisligil et al 1994; Hotamisligil 1999a, 
1999b). TNF-α has been implicated as a causative key 
mediator of insulin resistance through direct interference 
with insulin signal transduction, TNF-α is an activator of 
NF-κB (Yerneni et al 1999) and has been implicated in the 
pathogenesis of diabetic nephropathy (Moriwaki et al 2007). 
During the development of diabetic nephropathy, TNF-α has 
been shown to be expressed in renal glomeruli and proximal 
renal tubules (Nakamura et al 1993, Sugimoto et al 1999; 
DiPetrillo and Gesek 2004). Furthermore, disease progres-
sion is associated with increased serum concentrations of 
TNF-α and shows a positive correlation with urinary protein 
excretion (Hasegawa et al 1991; Kalantarina et al 2003). 
Additional studies have demonstrated that the administra-
tion of TNF-α impairs renal function (Schmidt et al 2007), 
and that inhibition of TNF-α decreases urinary albumin 
excretion in rats with experimental diabetes (Moriwaki et al 
2007). Cumulatively, the evidence suggests a direct role for 
TNF-α in the development of diabetic nephropathy, but the 
link to C-peptide remains controversial.
PI-3 kinase is necessary for cell proliferation and survival, 
and is involved in TNF-α signaling. The PI-3 pathway 
is implicated in the pathogenesis of diabetic endothelial 
dysfunction and atherosclerosis, and also this pathway 
has been shown to be increased by C-peptide (Brownlee 
2001; Grunberger et al 2001; Kitamura et al 2001; Li et al 
2003; Walcher et al 2006), implicating a synergistic effect 
of C-peptide and TNF-α in aggravating diabetes-associated 
complications. On the other hand, administration of 
C-peptide prevented TNF-α-mediated apoptosis in 
opossum proximal tubular cells (Al-Rasheed et al 2006), 
suggesting a protective role of C-peptide in the progression 
of diabetes-related kidney disease. Hence, the interactions 
between TNF-α and C-peptide occur on multiple levels and 
outcomes may differ between different organs.
In addition to its causal role in vascular disease, NF-κB 
is also essential for neuronal development and differentiation 
(Brand et al 1996; O’Neill and Kaitschmidt 1997; Denk et al 
2000). In neurons, it may play a pro- or antiapoptotic role, 
depending on the cell type and the state of the cell (Brand 
et al 1996; O’Neill and Kaitschmidt 1997; Denk et al 2000). 
In the presence of insulin, C-peptide has been shown to exert 
antiapoptotic effects on neuroblastoma cells, and to increase 
the production of NF-κB (Li et al 2003). C-peptide has been 
suggested to be beneﬁ  cial in diabetic neuropathy (Sima et al 
2004) by promoting neuronal development, regeneration and 
cell survival. C-peptide prevents neuronal apoptosis in type 1 
diabetes and in vitro, C-peptide induces neurite outgrowth 
and cell-growth of the neuroblastoma cell line SH-SY5Y 
(Li et al 2003; Li and Sima 2004).
To summarize, accumulating data suggest that C-peptide 
is involved in regulation of cell proliferation and apoptosis on 
multiple levels, mainly due to its association with inﬂ  amma-
tory mediators, such as NF-κB and TNF-α. C-peptide appears 
to have predominantly antiproliferative effects in smooth 
muscle cells and beneﬁ  cial roles in diabetic neuropathy, while 
renal effects of C-peptide remain controversial. C-peptide 
may, on the other hand, play a negative role in endothelial 
dysfunction due to activation of the PI-3 pathway.
Immunoregulatory effects 
of C-peptide
Nitric oxide synthase (NOS) and nitric oxide (NO) regulation 
are known to be altered in diabetic and inflammatory 
states (Scalia et al 2000; Langer et al 2002; Marx et al 
2004). C-peptide increases eNOS and NO activity (Johansson Vascular Health and Risk Management 2008:4(6) 1286
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et al 2003; Tsimaratos et al 2003; Walcher et al 2004; 
Maezawa et al 2006). In smooth muscle cells (Chakrabarti 
et al 2004) and aortic endothelial cells (Young et al 2000; 
Tsimaratos et al 2003), C-peptide has been shown to increase 
intracellular Ca2+, thereby inducing NO production by endo-
thelial NOS (eNOS) and iNOS, causing an NO-dependent 
vasodilation. In myocardial ischemia-reperfusion, C-peptide 
has been shown to exert cardioprotective effects through the 
release of NO (Young et al 2000).
The impaired release of NO from the vascular bed will 
up-regulate adhesion molecules on endothelial cells, thereby 
increasing leukocyte-endothelium interactions (known as 
“rolling” and “sticking”) (Scalia et al 2000). Early in the 
development of atherosclerosis, circulating monocytes adhere 
and migrate into the subendothelial space (Marx et al 2004). 
In isolated ischemic and reperfused rat hearts, C-peptide 
reduces polymorphonuclear cell adherence to vascular endo-
thelium (Young et al 2000), and in an in vivo rat model of 
inﬂ  ammatory vascular dysfunction, a single bolus injection 
of C-peptide decreased the expression of endothelial cell 
adhesion molecules on the rat microvascular endothelium, 
leading to reduced leukocyte rolling and adhesion as well as 
transmigration in mesenteric venules (Scalia et al 2000). This 
attenuation of leukocyte-endothelial interactions is mediated 
by an increase in eNOS synthesis and subsequent release of 
NO (Scalia et al 2000). Overall, these reports suggest that 
administration of C-peptide in physiological doses exerts 
antiinﬂ  ammatory, and thus antiatherosclerotic effects.
Paradoxically, C-peptide has also been reported to 
possess proinﬂ  ammatory properties. C-peptide improves 
dermal wound healing associated with an increased number 
of leukocytes adherent to the endothelium (Langer et al 
2002). C-peptide has been reported to co-localize with 
macrophages and monocytes in artery specimens from 
diabetic subjects (Marx et al 2004), and to co-localize with 
and act as a chemoattractant for CD4-positive lymphocyte 
and monocytes in early atherosclerotic lesions (Walcher 
et al 2004). In Swiss 3T3 ﬁ  broblasts, C-peptide (1 nM) has 
been shown to stimulate the transcription of inﬂ  ammatory 
genes, such as cyclooxygenase-2 (COX-2), via the activation 
of a PKC/NF-κB signaling pathway (Kitazawa et al 2006). 
In view of these potential effects of C-peptide, it is important 
to determine whether the net effect of C-peptide supplemen-
tation is beneﬁ  cial or detrimental for the development of 
diabetes-associated complications.
In summary, the role of C-peptide in the regulation of 
inﬂ  ammation remains controversial, and further studies are 
needed in order to determine in which contexts treatment with 




It has been suggested that C-peptide has effects on 
angiogenesis (Chakrabarti et al 2004). There are indica-
tions that diabetes induces the up-regulation of oncofetal 
ﬁ  bronectin in the retina (Khan et al 2004), a substance 
believed to be involved in angiogenesis and normally not 
found in mature tissue (Castellani et al 1994; Karelina 
and Eisen 1998). Increased retinal expression of oncofetal 
fibronectin in diabetic rats is completely prevented by 
C-peptide treatment (Chakrabarti et al 2004). This normal-
ization of the diabetes-induced up-regulation of oncofetal 
ﬁ  bronectin in diabetic retinas, may suggest an important role 
of C-peptide for the development of microangiopathy.
Conclusion
Given C-peptide’s effects on NF-κB, TNF-α, and PKC, 
plasma C-peptide concentrations may play a pivotal role 
in the regulation of endothelial function. Thus, prescribed 
to the right patients, it is likely that C-peptide substitution 
would reduce the prevalence of diabetes complications. 
Accumulated evidence suggest that exogenous C-peptide 
possesses beneﬁ  cial effects on diabetic complications in 
type 1 diabetic patients, and likely also in type 2 diabetic 
patients with relative C-peptide deﬁ  ciency. However, it may 
be that C-peptide does not prevent, but rather contributes to 
and promotes atherogenesis in patients with excess C-peptide 
production. It remains to be determined whether these 
seemingly divergent effects reﬂ  ect tissue- or state-speciﬁ  c 
mechanisms.
So far, C-peptide studies have given several opportu-
nities for new drug targets and research directions. Also, 
C-peptide-induced effects on NO production are not 
restricted to the diabetic state, but have been reported in 
models of ischemia-reperfusion as well as during inﬂ  am-
mation. Concomitantly, the effectiveness of C-peptide 
in the prevention and reversal of diabetic complications 
merits further investigation, particularly in human subjects. 
Protection from diabetes-induced vascular dysfunction by 
C-peptide administration has been reported in small-scale 
clinical trials (Johansson et al 2000; Hansen et al 2002), 
but long-term, large-scale studies need to be conducted in 
order to determine safety and health outcomes of long-term 
administration of C-peptide to patients with diabetes. It is not 
unlikely that C-peptide substitution in physiological doses Vascular Health and Risk Management 2008:4(6) 1287
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would improve endothelial dysfunction, prevent or induce 
the regression of the atherosclerotic lesions and reduce the 
risk of diabetes complications.
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